Lp(a)HORIZON reports neutral cardiovascular outcomes despite substantial pelacarsen biomarker reduction
Company / institutional announcement · Cleveland Clinic
Source published: · Event / reporting date: 2026-11-07
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.
Why it may matter
Potential business implication: biomarker reduction alone cannot establish clinical benefit; oligonucleotide programs need indication-specific outcome evidence and tolerability assessment.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections
Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development